Further research is needed to establish standardized treatment guidelines, assess long-term safety, and investigate the role of genetic factors (e.g., CYP enzyme polymorphisms) in antipsychotic metabolism and efficacy in AIP. The gene discussed is PPIG; the disease is autoimmune pancreatitis.